McGuire Investment Group LLC Cuts Stock Holdings in Danaher Co. (NYSE:DHR)

McGuire Investment Group LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 0.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,689 shares of the conglomerate’s stock after selling 111 shares during the quarter. McGuire Investment Group LLC’s holdings in Danaher were worth $8,192,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Decker Retirement Planning Inc. purchased a new stake in shares of Danaher during the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher in the third quarter worth approximately $39,000. MidAtlantic Capital Management Inc. purchased a new stake in Danaher in the third quarter worth approximately $40,000. FSA Wealth Management LLC purchased a new stake in Danaher in the third quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in Danaher in the third quarter worth approximately $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.1 %

DHR stock opened at $245.95 on Friday. Danaher Co. has a 1-year low of $225.42 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market capitalization of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The business has a 50 day simple moving average of $235.02 and a two-hundred day simple moving average of $253.41.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the company posted $2.02 EPS. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. Research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s payout ratio is 20.61%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DHR. Royal Bank of Canada dropped their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Citigroup dropped their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Evercore ISI raised their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.